China Healthcare Weekly (Apr14)- Shanghai Shyndec Pharma,Innovative Drug Policy,Ultra Long-Term Bond

380 Views14 Apr 2024 16:11
​China will issue special treasury bonds for healthcare.New policy boosts hope for innovative drugs.Horizontal competition in Taiji and Shanghai Shyndec Pharma may lead to spin-off/integration by 2025
What is covered in the Full Insight:
  • Medical Equipment Renewal Policy
  • Supporting Policies for Innovative Drug Industry
  • Investor Sentiment Towards China's Drug Industry
  • Competing Interests in the Chinese Pharmaceutical Landscape
  • Risk Factors
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x